Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

Valoctocogene Roxaparvovec (Roctavian; BioMarin Pharmaceutical) for Hemophilia A

Valoctocogene roxaparvovec (Roctavian; Biomarin Pharmaceutical Inc.) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 international unit/deciliter [IU/dL]) without pre-existing antibodies to adeno-associated virus serotype 5 detected by a U.S. ...

Vibrant System (Vibrant Gastro Inc.) for Chronic Idiopathic Constipation

The Vibrant vibrating capsule is an electric swallowable capsule that naturally passes through the gastrointestinal tract. It is indicated for the treatment of adults with chronic idiopathic constipation who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least 1 month.

TOPS System (Premia Spine) for Lumbar Spondylolisthesis With Spinal Stenosis

The TOPS System (Premia Spine) is a motion-preserving spinal implant indicated for patients between 35 and 80 years of age with symptomatic degenerative spondylolisthesis up to Grade I, with moderate to severe lumbar spinal stenosis and either the thickening of the ligamentum flavum and/or of the scarring facet joint capsule at one level from L3 to L5.

Detour System (Endologix LLC) for Percutaneous Femoropopliteal Bypass

The Detour System is an endovascular stent-graft bypass system indicated for percutaneous revascularization in patients with symptomatic long femoropopliteal lesions with chronic total occlusion or diffuse stenosis who are suboptimal candidates for surgical or other endovascular treatments.